• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 13, 2010

View Archived Issues

CTCs Now Prognostic But Not Predictive; That May Change

Circulating stem cells (CTCs), Minetta Liu told reporters at the 2010 San Antonio Breast Cancer Symposium, are "a hot topic. But . . . we actually don't know what they are." Read More

MIPI Files for Chapter 11, and Gets $45M Financing

Molecular Insight Pharmaceuticals Inc. will undergo a corporate reorganization under a Chapter 11 filing pursuant to a $45 million financing commitment from Savitr Capital LLC. Read More

EpiCept Shares Rise 38.6% on Ceplene Survival Analysis

EpiCept Corp. stock (NASDAQ:EPCT) climbed 38.6 percent, gaining 27 cents, to close at 97 cents Friday, following word from the Tarrytown, N.Y.-based company that a new analysis supported the favorable impact of Ceplene (histamine dihydrochloride) on overall survival and its activity with interleukin-2 (IL-2) in patients with acute myeloid leukemia (AML). Read More

Other News To Note

• MorphoSys AG, of Martinsried, Germany, said its subsidiary, Sloning BioTechnology GmbH, signed a nonexclusive license and technology transfer deal with Pfizer Inc., of New York, covering the installation, training and use of Sloning's Slonomics platform for fabrication of highly diverse gene and protein libraries and Pfizer's subsidiary, Rinat NeuroScience Corp. Read More

Stock Movers

Read More

Clinic Roundup

• Arena Pharmaceuticals Inc., of San Diego, started dosing in a Phase I trial of APD811, an oral candidate designed to target the prostacyclin receptor for treatment of pulmonary arterial hypertension. The study is expected to enroll up to 72 healthy adult volunteers to test single-ascending doses of the drug. Read More

Bench Press

Scientists from Vanderbilt University described why the 2009 pandemic H1N1 flu strain, as well as other pandemic strains, appeared to cause disproportionate damage in middle-aged individuals. While seasonal flu strains tend to pick off the very old, the very young and the immunocompromised, pandemic flu strains are often most deadly to the people best able to fend off other types of infectious diseases: healthy adults. Read More

Anaphore's Atrimers Snag up to $345M from Mitsubishi

Anaphore Inc. is expected to announce Monday morning that it has snagged its first big pharma partnership for its Atrimer protein engineering platform, a deal with Mitsubishi Tanabe Pharma Corp. that could be worth up to $345 million. Read More

Appeals Court Hears Human Embryonic Stem Cell Case

WASHINGTON – A district judge's interpretation of the Dickey-Wicker Amendment was "fundamentally flawed" when the court ruled that human embryonic stem cell (hESC) research was illegal, and therefore, the order should be reversed, a government lawyer argued last week before a three-judge panel from the U.S. Circuit Court of Appeals for the District of Columbia. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe